Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating H3K27me3 and H3K36me3 in advanced hepatocellular carcinoma patient...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Epigenomics 2022-05, Vol.14 (9), p.507-517
Hauptverfasser:	Salani, Francesca, Latarani, Maryam, Casadei-Gardini, Andrea, Gangadharannambiar, Priyadarsini, Fornaro, Lorenzo, Vivaldi, Caterina, Pecora, Irene, Massa, Valentina, Marisi, Giorgia, Canale, Matteo, Ulivi, Paola, Scartozzi, Mario, Eccleston, Mark, Masi, Gianluca, Crea, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	advanced disease epigenetic biomarkers EZH2 H3K27me3 H3K27me3/H3K36me3 ratio H3K36me3 HCC SETD2 sorafenib treatment prediction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!